Nabriva Therapeutics — Investor Presentation (November 2017)
57 slides from Nabriva Therapeutics's investor presentation, Nov 7, 2017
Slide 1: Forward-looking statements
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements about our future expectations, plans and prospects, including but not limited to sta
Slide 2: 2017 - A Transformational Year for Nabriva
Expert team advancing pleuromutilins, a new class of antibiotics, for systemic (IV and oral) use in humans Lefamulin in two global, pivotal Phase 3 trials for moderate-to-severe CABP with topline data received in September 2017 and expected for LEAP 2 in the spring of 2018 Investing in pre-commercia
Slide 3: Antimicrobial Resistance: A Serious Problem That Needs Serious Attention
By 2050, WHO estimates more deaths globally due to Resistant Bacteria than Cancer FUTURE ESTIMATED DEATHS ATTRIBUTABLE TO VARIOUS CAUSES Antimicrobial Resistance: A Serious Problem That Needs Serious Attention
Slide 4: Pneumonia: A Leading Cause of Morbidity, Mortality and Cost
Pneumonia: A Leading Cause of Morbidity, Mortality and Cost 5-6MM Approximately CABP cases annually Mortality rate for admitted patients Mortality rate for those who require admission to ICU Leading cause of infection death ~15% ~25 - 30% ~1st Sources: File TM Jr, Marrie TJ. Burden of community-acqu
Slide 5: Pleuromutilins Represent a New Class of Antibiotics for Systemic Human Use
Lefamulin A site P site PTC of the 23S rRNA of the large ribosomal subunit Pleuromutilins Represent a New Class of Antibiotics for Systemic Human Use Lefamulin: Novel mechanism of action with 4 distinctive binding sites in highly conserved core of the ribosomal peptidyl transferase center (PTC) Low
Slide 6: LEAP Trial Design and Demographics
LEAP 1 Trial Design and Demographics
Slide 7: LEAP Phase 3 Trial Design
LEAP 1 Phase 3 Trial Design IV Initiation with Option for Switch to Oral Administration Lefamulin (± Placebo) Moxifloxacin (± Linezolid) Informed Consent & Baseline Assessments Randomization Early Clinical Response (ECR) Assessment (96 +/- 24 hrs After 1st Dose) End of Treatment Within 2 Days After
Slide 8: LEAP Trial Populations, Disposition and Baseline Characteristics
LEAP 1 Phase 3 Trial Populations, Disposition and Baseline Characteristics Demographics 551 patients randomized (n = 276 for lefamulin vs 275 for moxifloxacin +/- linezolid) Comparable number of patients in each of the treatment arms in the modified ITT (mITT), clinically evaluable at test of cure (
Slide 9: LEAP Trial Efficacy Results
LEAP 1 Trial Efficacy Results
Slide 10: Lefamulin Meets FDA and EMA Primary Endpoints
LEAP 1 Trial Efficacy Results Lefamulin Meets FDA and EMA Primary Endpoints
Slide 11: ECR by Baseline Pathogen – Typical Pathogens
ECR by Baseline Pathogen – Typical Pathogens [micro ITT] Lefamulin Demonstrated High Response Rate Across All of the Most Common Causes of CABP Lefamulin Moxifloxacin (±linezolid) Microbiological ITT (microITT) N = 160 (58.0%) N = 159 (57.8%) Baseline Pathogen ECR (%) ECR (%) Gram Positive S. Pneumo
Slide 12: ECR by Baseline Pathogen – Typical and Atypical Pathogens
ECR by Baseline Pathogen – Typical and Atypical Pathogens [micro ITT] High Response Rate Seen Across All of the Most Common Causes of CABP Lefamulin Moxifloxacin (±linezolid) Baseline Pathogen ECR (%) ECR (%) Gram Negative H. influenzae 8/8 100% 6/7 85.7% M. catarrhalis 47/52 90.4% 52/55 94.5% Atypi
Slide 13: LEAP Trial Safety and Tolerability Data
LEAP 1 Trial Safety and Tolerability Data
Slide 14: Overview of Adverse Events
Overview of Adverse Events Low Rates of Discontinuation Observed Patients with at Least One Lefamulin (n=273) Moxifloxacin (±linezolid) (n=273) Adverse Events (AE) 105 (38.5%) 105 (38.5%) Treatment Emergent AE (TEAE) 104 (38.1%) 103 (37.7%) Serious AE (SAE) 19 (7.0%) 13 (4.8%) Related AE 41 (15.0%)
Slide 15: Treatment Emergent Adverse Events of Interest
Treatment Emergent Adverse Events of Interest TEAEs in 6.6% and 13.0% of subjects receiving lefamulin and moxifloxacin (±linezolid), respectively No cases of Clostridium difficile infection were reported in either treatment group Diarrhea was observed in 0.7% and 7.7% of subjects receiving lefamulin
Slide 16: TEAEs > 2% for Study Medication
TEAEs > 2% for Study Medication: Safety Population Lefamulin was Well Tolerated with a Lower Incidence of Diarrhea Preferred Term Lefamulin (n=273) Moxifloxacin (±linezolid) (n=273) Hypokalemia 8 (2.9%) 6 (2.2%) Nausea 8 (2.9%) 6 (2.2%) Insomnia 8 (2.9%) 5 (1.8%) Infusion Site Pain 8 (2.9%) 0 (0.0%)
Slide 17: Maximum Post Baseline Liver Enzymes
Maximum Post Baseline Liver Enzymes: Safety Population Low Incidence of Elevated Liver Function Tests Lab Parameter Lefamulin Moxifloxacin (±linezolid) Any Post Baseline ALT >3xULN 19/268 (7.1%) 17/267 (6.4%) >5xULN 6/268 (2.2%) 5/267 (1.9%) >10xULN 1/268 (0.4%) 0/267 (0.0%) Any Post Baseline AST >3
Slide 18: Maximum Post Dose QTcF Changes
Maximum Post Dose QTcF Changes (Day 3) Parameter Lefamulin Moxifloxacin (±linezolid) Post Dose Increase 30 - 60 msec 12 (4.6%) 14 (5.4%) Post Dose Increase > 60 msec 0 (0.0%) 1 (0.4%) Post Dose Value > 500 msec 1 (0.4%) 1 (0.4%)
Slide 19: LEAP Phase 3 Clinical Trial Highlights
LEAP 1 Phase 3 Clinical Trial Highlights Lefamulin is the first of a new class of antibiotics with favorable Phase 3 data in CABP in more than 15 years Lefamulin’s efficacy data - in our first trial treating adults with CABP - was comparable to a gold standard therapy Lefamulin showed a favorable to
Slide 20: LEAP 2: Next Significant Clinical Milestone
LEAP 2: Next Significant Clinical Milestone LEAP 1 (IV to Oral) Trial 551 adult patients with PORT Risk Class ≥III (moderate to severe) 1:1 randomization: lefamulin vs. moxifloxacin ± linezolid Rx for 7 days (10 days for MRSA) PORT Risk Class III vs. IV and V ≥25% of patients will have a PORT risk c
Slide 21: Lefamulin: A Significant Commercial Opportunity in CABP
5-6MM Pts/year in the US, #1 cause of Infectious Deaths, #2 cause of Hospitalization and #3 cause of Hospital Readmissions, and it’s very costlyA Current available treatments for CABP have limitations due to increased resistance and Collateral Damage Lefamulin has profile well suited for CABP with e
Slide 22: Pneumonia: A Leading Cause of Morbidity, Mortality and Cost
Pneumonia: A Leading Cause of Morbidity, Mortality and Cost 5-6MM Approximately CABP cases annually Sources: File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130–41. Fingar K, Washington R. Trends in hospital readmissions for four high-vo
Slide 23: CABP: Current Antibiotic Treatment Landscape
Sources: (1) AMR data 2015 (2) Based on 6-12-17 data provided by Source Health Solutions (12 months ending September 2016), Age 18+ (3) IMS Data 2010-2015 (4) IDSA/ATS Treatment Guidelines recommendation (Mandell L. et al Clin Infect Dis. 2007; 44 (Supplement 2) :S27-S72) CABP: Current Antibiotic Tr
Slide 24: 1/3 of all CABP Patients Need 2nd or 3rd Line Therapy
1/3 of all CABP Patients Need 2nd or 3rd Line Therapy A which can Increase Length and Cost of Hospital Stay B A Company sponsored market research, Medical Marketing Economics, July 2016, (N=122) B Company sponsored market research, Avalere 2016 Analysis of CABP 2015 MedPAR data Percent of CABP patie
Slide 25: Bacterial Resistance and Collateral Damage
Bacterial Resistance and Collateral Damage: Complicates the Choice of Appropriate Empiric Therapy aMorrissey, I. ECCMID 2014. Abstract P1584 bKim, SH AAC, 2012, 56: 1418-1426 Classi P et al. The relationship between macrolide-resistant Streptococcus pneumoniae and treatment failure in adults with co
Slide 26: Bacterial Resistance and Collateral Damage: C. Difficile Risk
Bacterial Resistance and Collateral Damage: Complicates the Choice of Appropriate Empiric Therapy Fluorquinolones & Cephalosporins have a High Risk Index for the development of Clostridium Difficile Infections Sources: Antimicrobial Agents and Chemotherapy p. 2326-2332 May 2013 Volume 57 Number 5 Fl
Slide 27: Antibiotic Stewardship: Appropriate Antibiotic Therapy is Essential
Antibiotic Stewardship: Appropriate Antibiotic Therapy is Essential 1. Dellit TH et.al., Clin Infect Dis (2007) 2. Amin AN et.al., Mayo Clin Proc (2014) 3. Slama TG, Alpesh Amin et.al., Am Jour Med (2005) Overuse of Broad Spectrum Antibiotics Antimicrobial Resistance & Collateral Damage (e.g. C. Dif
Slide 28: Lefamulin: Well Suited to Treat CABP
Lefamulin: Well Suited to Treat CABP - Consistent with all the Key Principles of Antimicrobial Stewardship - New Class New Mechanism of Action Effective against resistant pathogens and no cross –resistance to antibiotics commonly used for CABP Low propensity for resistance development Complete Spect
Slide 29: Lefamulin Profile Suited for Distinct Opportunities in CABP
Lefamulin Innovative Profile is Well Suited for 3 Distinct and Significant Opportunities in the Treatment of CAPB Total Addressable Population Market Share Scenario*C 1st Empiric TherapyC: ~90% Hospital In Patient ~3.0MMA 2nd-3rd Line TherapyC: ~30% ~2.7 MM Patients ~0.9 MM Patients ~5% ~10% 135K Pt
Slide 30: Commercialization Strategy Designed to Accelerate Lefamulin Adoption
~1600 Hospitals represent ~80% Market Potential for Hospital-Initiated CABP Treatments Sources: Symphony Data 2016 STEP 1 (Pre-Launch): Talented and experienced Medical Affairs Team (MSLs) & Commercial Development Team (MDDs) Medical Education: Disease Awareness Campaign(s) Surveillance & Health Eco
Slide 31: Financial Highlights
Financial Highlights $126.5MM Cash, cash equivalents and short term investments Proforma as of June 30, 2017 Current cash resources expected to fund operations into Q4 ‘18 36.6MM ordinary shares as of September 20, 2017 Exchange offer to redomicile from Austria to Ireland completed
Slide 32: Recent and Anticipated Lefamulin Milestones
Sept 2017 Topline data from LEAP 1 Phase 3 trial for CABP Q4 2017 Completion of enrollment for LEAP 2 Recent and Anticipated Lefamulin Milestones Spring 2018 Topline data from LEAP 2 Phase 3 trial for CABP 2H 2018 Regulatory filing in US (priority review request to FDA) for CABP
Slide 33: Positioned for Long-Term Growth and Success
Positioned for Long-Term Growth and Success CABP represents a significant medical need Rising rates of bacterial resistance to commonly used antibiotic therapies Utility of available treatment options becoming more limited Lefamulin is well-positioned to potentially address limitations of current an
Slide 34: Developing Novel Anti-Infectives
Fall 2017 Developing Novel Anti-Infectives
Slide 35: Nabriva Therapeutics: Novel Anti-Infectives
en nabriva ‘THERAPEUTICS. Novel Anti-Infectives
Slide 36: Lefamulin has a Differentiated Profile for CABP
Lefamulin has a Differentiated Profile for CABP 37 Lefamulin Macrolides Cephalo-sporins Linezolid and Tedizolid Tetracyclines, including Omadacycline Fluoro-Quinolones Including Delafloxacin New Class, New MoA for CABP Ideal CABP Spectrum, Including Atypical & MRSA PK/PD Profile IV & Oral Short Cour
Slide 37: LEAP Phase 3 Trial Design: FDA and EMA Primary Endpoints
LEAP 1 Phase 3 Trial Design FDA and EMA Primary Endpoints At 72 to 120 hours after first dose of study drug: Improvement in ≥ 2 of 4 CABP signs/symptoms No worsening in any CABP signs/symptoms Alive Did not receive non-study antibacterial therapy for the treatment of CABP Non-inferiority margin 12.5
Slide 38: LEAP 1 and 2: Powering and Primary Objectives
LEAP 1 and 2: Powering and Primary Objectives FDA Endpoint: Early Clinical Response (ECR) 72-120 hours after first dose of study drug Intent to Treat (ITT) Population LEAP 1 non-inferiority margin 12.5%, >90% power LEAP 2 non-inferiority margin 10%, 90% power EMA endpoint: Investigator Assessment of
Slide 39: LEAP 1 and 2: Treatment Scenarios
LEAP 1 and 2: Treatment Scenarios LEAP 1 All patients: IV therapy for a minimum of three days before switching to oral therapy Patients will receive 7 days of lefamulin vs. 7 days moxifloxacin Patients receive 10 days if: MRSA pneumonia confirmed Both moxifloxacin and linezolid started at baseline (
Slide 40: Symptom Assessment for ECR
LEAP 1 Phase 3 Trial Design Symptom Assessment for ECR Symptom Absent (0) Mild (1) Moderate (2) Severe (3) Dyspnea Resolution (to pre-CABP baseline) or absence of dyspnea Dyspnea on exertion (e.g., climbing stairs) Dyspnea with normal/routine activities (e.g., walking) Dyspnea at rest or requiring o
Slide 41: LEAP Trial Populations and Disposition
LEAP 1 Phase 3 Trial Populations and Disposition High Patient Completion and Microbiological Isolate Recovery Rates Category Lefamulin Moxifloxacin (±linezolid) TOTAL All Randomized 276 275 551 Modified ITT (mITT) 273 (98.9%) 273 (99.3%) 546 (99.1%) Clinically Evaluable-Test of Cure (CE-TOC) 236 (85
Slide 42: LEAP Trial ITT Population Balanced Demographics
LEAP 1 Phase 3 Trial ITT Population Balanced Demographics Between Treatment Groups Category Lefamulin Moxifloxacin (±linezolid) TOTAL Age (Years; Mean) 61.0 59.6 60.3 <65 years 144 (52.2%) 167 (60.7%) 311 (56.4%) 65-74 74 (26.8%) 66 (24.0%) 140 (25.4%) ≥75 58 (21.0%) 42 (15.3%) 100 (18.1%) Gender Ma
Slide 43: PORT Risk Classification: ITT Population
LEAP 1 Phase 3 Trial PORT Risk Classification: ITT Population Moderate to Severe Pneumonia Patients PORT Class Lefamulin Moxifloxacin (±linezolid) TOTAL II 0 1 (0.4%) 1 (0.2%) III 196 (71.0%) 201 (73.1%) 397 (72.1%) IV 76 (27.5%) 70 (25.5%) 146 (26.5%) V 4 (1.4%) 3 (1.1%) 7 (1.3%)
Slide 44: ECR by PORT Risk Classification
ECR by PORT Risk Classification: ITT Population Lefamulin Demonstrated High Response Rates Across All Severities of CABP PORT Class Lefamulin Moxifloxacin (±linezolid) Treatment Difference (95% CI) II 0 1/1 (100%) -- III 175/196 (89.3%) 187/201 (93.0%) -3.7 (-9.8, 2.3) IV 63/76 (82.9%) 57/70 (81.4%)
Slide 45: Lefamulin Spectrum of in vitro Activity Well Suited for CABP
Lefamulin Spectrum of in vitro Activity Well Suited for CABP Extensively investigated against most prevalent pathogens Not affected by increasing antibiotic resistance observed in CABP pathogens: Cephalosporin/ fluoroquinolone/ macrolide/ penicillin resistance in S. pneumoniae Macrolide-resistant My
Slide 46: Therapeutic Effect Observed in Phase 2 Trial of ABSSSI
Therapeutic Effect Observed in Phase 2 Trial of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Lefamulin achieved clinical response rates comparable to vancomycin Lefamulin was well tolerated Most commonly reported adverse events included headache, nausea and infusion site pain or redne
Slide 47: Lefamulin Tolerability Profile Observed in Phase 2 Trial of ABSSSI
Lefamulin Related Tolerability Profile Observed in Phase 2 Trial of ABSSSI
Slide 48: Lefamulin Clinical Development Plan Supports Differentiation in CABP
Lefamulin Clinical Development Plan Supports Differentiation in CABP Phase 3 CABP registration program initiated in the fall of 2015 Lefamulin Evaluation of Adults with Pneumonia (LEAP 1) trial (IV to oral): moderate-to-severe CABP (Pneumonia Outcomes Research Team (PORT) III, IV and V) February 201
Slide 49: Lefamulin Manufacturing On Track for NDA Submission in 2018
Lefamulin Manufacturing On Track for NDA Submission in 2018 Nabriva CMC/Manufacturing Team- extensive experience with new product approvals in the US and Europe Nabriva Quality Assurance Team- extensive experience with regulatory agency requirements in the US and Europe Drug Substance (API) Well kno
Slide 50: Nabriva Has a Strong and Broad Patent Portfolio
Nabriva Has a Strong and Broad Patent Portfolio Nabriva currently has 19 worldwide pleuromutilin patent families active on file Most of the global pleuromutilin IP landscape is covered (including U.S., Europe, Japan) Lefamulin IP protected at least until 2028 by several layers Composition of matter
Slide 51: Antibiotic Stewardship Should Increasingly Drive Antibiotic Choices
Antibiotic Stewardship Should Increasingly Drive Antibiotic Choices Effective January 1st 2017, Joint Commission & CMS require that all hospitals have Antibiotic Stewardship Committees (ASC) - Goalsa Achieve the best clinical outcome, while lessening or mitigating adverse events and limiting selecti
Slide 52: CABP Treatment Guidelines
Non-ICU Inpatient B-lactam (IV or IM) + Macrolide (IV or PO) Respiratory Quinolone (IV or PO) B-lactam (IV or IM) + Doxycycline (IV or PO) ICU Inpatient B-lactam (IV) + Macrolide (IV) B-lactam (IV) + respiratory Quinolone (IV) B-lactam (IV) + Aminoglycoside (IV) + respiratory Quinolone (IV) Mandell
Slide 53: Agencies Focused on Infectious Diseases
US legislation continues to drive discovery of novel antibiotics GAIN Act (Generating Antibiotic Incentives Now) ADAPT Act (Antibiotic Development to Advance Patient Treatment) DISARM Act (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms)- part of 21st Century Cures Act C
Slide 54: WHO Top Priority Pathogens for which New Antibiotics are Urgently Needed
WHO Top Priority Pathogens for which New Antibiotics are Urgently Needed PRIORITY Critical Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant Enterobacteriaceae carbapenem-resistant ESBL-producing PRIORITY High Staphylococcus aureus, methicillin-resistant, van
Slide 55: References to Slide 30 (Commercial Assessment)
56 A: Healthcare Cost and Utilization Project (HCUP) 2013, Age 18+ (projected to 2029) B: Community Data (CDC 2009-2010), Age 18+ (projected to 2029) C: Company Sponsored Market Research, Medical Marketing Economics, July 2016, (N=122) References to Slide 30 (Commercial Assessment)
Slide 56: Advancing Pleuromutilin Development Pipeline
Advancing Pleuromutilin Development Pipeline Program Indications Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Comments Lefamulin (IV/oral) CABP* LEAP 1 topline data announced in Sept 2017 and LEAP 2 topline data expected in spring 2018 ABSSSI Phase 2 complete Lefamulin (IV/oral) Pediatric Indicati
Slide 57: Advancing Pleuromutilin Development Pipeline
Advancing Pleuromutilin Development Pipeline Lefamulin spring 2018 Lefamulin Pediatric ‘and formulation Lefamulin Osteomyelitis, Potential Other han LEAP 1, we have not competed any cial tis of leftamuin specticaly fr patients wth CABP.
Nabriva Therapeutics — Investor Presentation (November 2017) on 6ix